Back to Search
TAKEIYA LYNCH, MD
MD
Psychiatry Physician
NPI: 1417577891Individual
Specialties, Licenses & Credentials
Psychiatry PhysicianPrimary
Psychiatry & Neurology — Psychiatry
Code: 2084P0800X
1013066(MA)
Research & Publications (20)
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.
PMID 19633475·J Thorac Oncol·2009
3-trial
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
PMID 18520291·J Thorac Oncol·2008
8-other
Novel agents in the treatment of lung cancer: Fourth Cambridge Conference.
PMID 17671145·Clin Cancer Res·2007
7-preclinical
Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
PMID 17522250·Oncologist·2007
6-review
Incorporation of recreational fishing effort into design of marine protected areas.
PMID 17002764·Conserv Biol·2006
8-other
Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.
PMID 16857812·Clin Cancer Res·2006
7-preclinical
Medication costs as a primary cause of nonadherence in the elderly.
PMID 16524358·Consult Pharm·2006
8-other
Optimizing chemotherapy and targeted agent combinations in NSCLC.
PMID 16551519·Lung Cancer·2005
8-other
Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement.
PMID 16000599·Clin Cancer Res·2005
8-other
Optimizing chemotherapy and targeted agent combinations in NSCLC.
PMID 16557671·Lung Cancer·2005
6-review
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 26-2004. A 56-year-old woman with cough and a lung nodule.
PMID 15317895·N Engl J Med·2004
5-case
Conflict and impacts of divers and anglers in a marine park.
PMID 15285398·Environ Manage·2004
7-preclinical
Novel agents in the treatment of lung cancer: conference summary statement.
PMID 15217958·Clin Cancer Res·2004
8-other
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
PMID 15118073·N Engl J Med·2004
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Quick Facts
- NPI
- 1417577891
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 3
- Publications
- 20
Are you this provider?
Claim Your Profile